Supernus Pharma (SUPN) Tops Q4 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
Supernus Announces Record Full Year 2018 Financial Results
February 26, 2019 4:56 PM ESTFourth quarter 2018 total revenue of $115.9 million, a 31% increase over 2017, and fourth quarter 2018 net product sales of $113.5 million, a 32% increase over 2017.Fourth quarter 2018 operating earnings of $39.9 million, a 16% increase over 2017.Full year 2018 total revenue of $408.9 million, a 35% increase over 2017. Full year 2018 net product sales of $399.9 million, a 36% increase over 2017.Full year 2018 operating earnings of $144.4 million, a 45% increase over 2017.Positive results from three Phase III studies for SPN-812 in ADHD announced in December 2018.Oxtellar XR® launched in January 2019 with expanded indication to include monotherapy for partial seizures.
ROCKVILLE, Md., Feb. 26, 2019 (GLOBE NEWSWIRE) --... More
